FDA Alert: Rituxan (rituximab) - PML

Links shared publicly online about this topic.

  • 1,653
    total visits

FDA Alert: Rituxan (rituximab) - PML

drugs.com

FDA Alert: Rituxan (rituximab) - PML

View full resource at drugs.com

Tags: Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, FDA, Rituxan, MabThera

  • Share

Most Recently Shared on October 24, 2009 at 2:10 pm By:

Medical News: FDA Okays Drug for Rare Blood Vessel Disorders - in Public Health & Policy, FDA General from MedPage Today

medpagetoday.com — “WASHINGTON -- The FDA approved the non-Hodgkin's lymphoma treatment rituximab (Rituxan) for use with steroids in patients with two rare blood-vessel inflammation disorders.View full resource at medpagetoday.com

  • View Related
  • Share

Most Recently Shared on April 21, 2011 at 4:17 pm By:

MedicalNews Medical News Health News

FDA Okays Drug for Rare Blood Vessel Disorders http://bit.ly/fJA9MR

1 year ago...

Rituxan Gains Indication for Severe Vasculitis - MPR

empr.com — “The FDA has approved Rituxan (rituximab; Genentech) in combination with corticosteroids for the treatment of adults with Wegener--™s granulomatosis and microscopic polyangiitis, two forms of severe ANCA-associated vasculitis.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on April 20, 2011 at 2:16 pm By:

eMPR MPR Medical Publisher

MPR News: Rituxan Gains Indication for Severe Vasculitis: The FDA has approved Rituxan (rituximab; Genentech) in... http://bit.ly/hHmGuo

1 year ago...

Rituxan Gains Indication for Severe Vasculitis - ONA

oncologynurseadvisor.com — “The FDA has approved Rituxan (rituximab; Genentech) in combination with corticosteroids for the treatment of adults with Wegener--™s granulomatosis and microscopic polyangiitis, two forms of severe ANCA-associated vasculitis.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on April 20, 2011 at 2:07 pm By:

FDA Approves Rituxan To Treat Two Rare Disorders

medicalnewstoday.com — “The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyaView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on April 20, 2011 at 8:05 am By:

Rituxan gains indication for first-line maintenance use in follicular lymphoma - ONA

oncologynurseadvisor.com — “Genentech announced that the FDA has approved Rituxan (rituximab) as maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on January 31, 2011 at 4:40 pm By:

ONAcom OncologyNurseAdvisor Medical Publisher, Oncology, Nursing, and Medical Education

Rituxan gains indication for first-line maintenance use in follicular lymphoma http://goo.gl/fb/w6938

1 year ago...

Rituxan gains indication for first-line maintenance use in follicular lymphoma - MPR

empr.com — “Genentech announced that the FDA has approved Rituxan (rituximab) as maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on January 31, 2011 at 4:18 pm By:

eMPR MPR Medical Publisher

MPR News: Rituxan gains indication for first-line maintenance use in follicular lymphoma: Genentech announced th... http://bit.ly/hWnvVc

1 year ago...

Rituximab Approved as Lymphoma Maintenance - QualityPoint Technologies

qualitypointtech.net — “(MedPage Today) -- The FDA has approved use of rituximab (Rituxan) as maintenance therapy for advanced follicular lymphoma in patients with an initial response to induction therapy with the drug plus chemotherapy, its manufacturers said.View full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on January 29, 2011 at 1:47 pm By:

MedicalFeed MedicalFeed Health News Feed

Rituximab Approved as Lymphoma Maintenance: (MedPage Today) -- The FDA has approved use of rituximab (Rituxan) as ... http://bit.ly/e9Ajrq

1 year ago...

FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia

drugs.com — “Rituxan (rituximab) is used to treat Chronic Lymphocytic Leukemia. Includes Rituxan side effects, interactions and indications.View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on February 22, 2010 at 11:41 pm By:

drugscom Drugs.com Health Site

FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia - http://bit.ly/960vQR

2 years ago...

US FDA Approves Rituxan/MabThera For The Most Common Type Of Adult Leukemia

medicalnewstoday.com — “Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for peopleView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on February 20, 2010 at 4:06 pm By:

mnt_leukemia MNT Leukemia Health News

US FDA Approves Rituxan/MabThera For The Most Common Type Of Adult Leukemia http://mnt.to/3xV7 #lymphoma #leukemia

2 years ago...

Rituxan approved for chronic lymphocytic leukemia - MPR

empr.com — “The FDA has approved Rituxan (rituximab, from Genentech) in combination with fludarabine and cyclophosphamide (FC) for patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on February 19, 2010 at 3:50 pm By:

eMPR MPR Medical Publisher

MPR News: Rituxan approved for chronic lymphocytic leukemia: The FDA has approved Rituxan (rituximab, from Genente... http://bit.ly/deIPpG

2 years ago...

Supplemental BLAs submitted for Rituxan for chronic lymphocytic leukemia - MPR

empr.com — “Genentech and Biogen Idec announced that they submitted two supplemental Biologics License Applications (sBLAs), along with a priority review request, to the FDA for Rituxan (rituximab) plus standard (fludarabine and cyclophosphamide) chemotherapy for patients with previously untreated or treated chronic lymphocytic leukemia (CLL).View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on May 20, 2009 at 9:30 pm By:

eMPR MPR Medical Publisher

MPR News: Supplemental BLAs submitted for Rituxan for chronic lymphocytic leukemia: Genentech and Bioge.. http://tinyurl.com/posl4z

3 years ago...

Advertisement